Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760161 | 1.00 | POLB (0.39) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL30229890 | 1.00 | POLB (0.39) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL2540013 | 1.00 | POLB (0.39) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL10361083 | 0.81 | ITGB1 (0.39) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL10362062 | 0.81 | ITGB1 (0.39) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL6942583 | 0.81 | ITGB1 (0.39) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL18237176 | 0.78 | ITGB1 (0.43) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL10415303 | 0.75 | ITGB1 (0.40) | POLBITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL5158369 | 0.74 | FKBP1A (0.47) | — | |
| SCHEMBL10414801 | 0.73 | MAPT (0.33) | POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152014-B2 | Therapeutic compounds and compositions | eXlthera Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118922424-A | Preparation method of 2-aminopyridine derivative | 西藏海思科制药有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| US-11691962-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| CN-112996495-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-111902404-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| WO-2018118705-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-3102200-A2 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-1089973-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6211170-B1 | Azetidinone derivatives for the treatment of HCMV infections | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-04-03 | — | — | US | disclosed |
| EP-1061936-A1 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | GEORGETOWN UNIVERSITY (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999067215-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999040931-A1 | CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS INJURY AND NEURODEGENERATIVE DISORDERS | GEORGETOWN UNIVERSITY (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0204440-B1 | AZETIDINE DERIVATIVES PRODUCTION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| EP-0171159-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, THEIR PREPARATION, AND MEDICAMENTS CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4719207-A | CENTRAL NERVOUS SYSTEM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-01-12 | — | — | US | disclosed |
| EP-0204440-A1 | Azetidine derivatives production | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
| EP-0171159-A1 | Substituted azetidinone compounds, their preparation, and medicaments containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059670-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | POLB 4497/4885ITGB1 3130/4885ITGA5 1513/4885 |
| US-20210188812-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | POLB 4497/4885ITGB1 3130/4885ITGA5 1513/4885 |
| US-12152014-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | POLB 4497/4885ITGB1 3130/4885ITGA5 1513/4885 |
| US-11691962-B2 | Therapeutic compounds and compositions | KLK5, KLK2, KLKB1 | POLB 4497/4885ITGB1 3130/4885ITGA5 1513/4885 |
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | POLB 4497/4885ITGB1 3130/4885ITGA5 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.